Femara early adjuvant approval
This article was originally published in Pharmaceutical Approvals Monthly
Novartis' aromatase inhibitor Femara (letrozole) clears FDA Dec. 28 for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer. Femara is the only medicine in its class approved for use in that setting as well as in the extended adjuvant setting following tamoxifen, Novartis says. Approval is based on the 8,000-patient Breast International Group (BIG 1-98) study showing an additional 21% reduction in risk of recurrence over tamoxifen (1Pharmaceutical Approvals Monthly August 2005, p. 13). Novartis' promotion of the new indication will be boosted by publication of the pivotal data supporting the sNDA in the Dec. 29 issue of The New England Journal of Medicine...
You may also be interested in...
Novartis is on track for a full range of indications for its breast cancer therapy Femara with a supplemental submission for early adjuvant use.
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
Executive orders signed by Joe Biden in the first days of his presidency to support the US pandemic response – including calling for a plan to bolster domestic manufacturing capabilities – have received a warm welcome from the AAM.